A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.
The emergence of cholera in Haiti once again reminds us of the ferocity with which infectious diseases can strike and of the complex interactions of emerging infectious diseases with social conditions, human migration, and the ecosystem.
Location:Hilton Am Stadtpark, Vienna, Austria
Organized by:International Society for Infectious Diseases (ISID)